Clinical Trial

Depth of Botulinum Neurotoxin Injection for Treatment of Glabellar Lines

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
STUDY QUESTION: Does the depth of injection of onabotulinumtoxinA neurotoxin in the glabellar complex affect efficacy of the BoTN for the improvement of glabellar frown lines? STUDY AIM * Primary objective: Compare the efficacy of onabotulinumtoxinA neurotoxin injected at the depth of 2mm vs 4mm for the improvement of glabellar lines * Secondary objective: Determine any adverse effects of onabotulinumtoxinA neurotoxin injected at the depth of 2mm vs 4mm RATIONALE FOR THE PROJECT: Although the use of BoTN for treatment of glabellar lines has long been established as safe and effective, the optimal depth of injection has not been established. Our project hopes to establish the optimal depth of injection for onabotulinumtoxinA neurotoxin for maximal improvement of glabellar lines with minimal adverse effects
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2023-03-09; most recent amendment 2026-03-10.
Status change: Not Yet Recruiting → Active, Not Recruiting 2023-03-23
Trial Details
NCT Number NCT05766683
Lead Sponsor Henry Ford Health System
Conditions Glabellar Frown Lines
Enrollment 20 participants
Start Date 2023-03-14
Primary Completion 2023-06-20 (estimated)
Study Completion 2026-12 (estimated)
Updated on ClinicalTrials.gov 2026-03-12